Stanford inventors have developed a novel diagnostic tool that identifies distinct immune signatures in the peripheral blood of osteoarthritis patients using mass cytometry (CyTOF) and applied machine learning.
Stanford inventors have developed a single cell screening platform that can be used to predict the therapeutic effects of osteoarthritis (OA) drugs on individual patients by defining consequent changes in the cellular landscape.
Stanford researchers have identified a biomarker on cartilage precursor cells that predicts which cells will develop into inflammation-resistant and functionally appropriate tissue for autologous transplants to treat osteoarthritis.
Researchers at Stanford have discovered that treatment with JNK II inhibitor and IBMX has a synergistic therapeutic effect against osteoarthritis (OA).